Scott Gottlieb

Guests Steve Witkoff, Trump's former top negotiator, discusses the complexities of Middle East peace talks and the delicate balance in Israel-Hamas negotiations. Former FDA commissioner Scott Gottlieb highlights the urgent public health crises, focusing on alarming measles outbreaks and the need to combat vaccine misinformation. They dive into the repercussions of workforce cuts in health agencies and how these changes could affect American health oversight moving forward. Expect a thought-provoking discussion on governance, health, and international diplomacy.

This podcast features Scott Gottlieb, the former FDA Commissioner and current board member for Pfizer, who discusses the vital effects of funding cuts on health research and the innovation pipeline. Additionally, investor Steve Eisman shares his outlook on market risks tied to the Israel-Iran conflict and the potential for a trade war, offering his unique insights on navigating these turbulent times. The discussion also hints at the emerging drama between OpenAI and Microsoft and the public market ambitions of crypto billionaire Justin Sun.

Scott Gottlieb, former FDA commissioner and healthcare expert, and Patrick Boyle, financial commentator and YouTuber, dive into pressing topics. They explore the political implications of vaccine announcements and transparency issues with big pharma, specifically Pfizer. The conversation shifts to the fintech landscape, discussing the risks of debanking practices and regulatory scrutiny. Gottlieb and Boyle also touch on the geopolitical landscape, with insights into the Ukraine conflict and its broader implications for international relations.

Dan Niles, a tech investor and founder of Niles Investment Management, discusses the surge in technology stocks and the implications of AI on investment strategies. He highlights Google's milestone of a $3 trillion market cap and the bullish sentiment surrounding Apple’s new iPhones. Scott Gottlieb, former FDA Commissioner, examines vaccine-related news and upcoming CDC policies, emphasizing public health trends and regulatory challenges. Together, they explore the intersection of tech and healthcare, shedding light on current market dynamics and future prospects.

Scott Gottlieb, former FDA commissioner and board member at Pfizer and Illumina, discusses the stark divide between Nvidia and Broadcom in the semiconductor market. He delves into the implications of a weaker jobs report, which raises the prospect of a September rate cut by the Fed, signaling a potentially weakening economy. Gottlieb also examines how this volatility in tech stocks could influence broader market dynamics, alongside concerns about sustainability in the AI sector amidst these economic challenges.

Scott Gottlieb, former head of the FDA and author of 'Uncontrolled Spread,' dives into the lessons learned from the COVID-19 pandemic. He discusses the critical role technology, particularly mRNA vaccine development, played in pandemic response and highlights failures in regulatory translation of science to policy. Joining him are Marc Andreessen, a prominent venture capitalist, and Vineeta Agarwala, a bio expert. They explore the need for improved genomic surveillance, private sector involvement in health infrastructure, and the ethical dilemmas of challenge trials for future preparedness.

Vivek Ramaswamy, an Ohio gubernatorial candidate and entrepreneur, joins former FDA Commissioner Scott Gottlieb for a riveting discussion on the alarming decline in American support for capitalism. They dissect the rise of socialist sentiments and tackle the national affordability crisis. Gottlieb also sheds light on vaccine access issues, influenced by current political dynamics. Together, they explore the challenges of housing affordability and the pressing need for innovative solutions to elevate the American economic landscape.

Senator Elizabeth Warren, a key Democratic voice in banking, challenges Fed Chair Jay Powell on interest rates and inflation, discussing economic policies that affect everyday Americans. Meanwhile, Dr. Scott Gottlieb, former FDA Commissioner, reveals insights on the CDC's shifting vaccine strategies amidst rising anti-vaccine sentiment. The duo navigates the intersection of economic decisions and public health initiatives, highlighting the importance of balanced policies and the ongoing debate around vaccine safety and accessibility.

Glenn Youngkin, Governor of Virginia and former CEO, discusses the impact of federal policies on Virginia's economy. He expresses optimism despite job losses related to the DOGE phenomenon. Dr. Scott Gottlieb, former FDA Commissioner, highlights concerns over rising costs in the pharmaceutical industry, warning that major medications could face production halts. The discussion also touches on the Trump administration's freeze on $2.2 billion in grants to Harvard, sparking a debate on free speech and government interference in education.

Makan Delrahim, former antitrust assistant attorney general, shares insights on the future of mergers and acquisitions under Trump's administration, emphasizing the cautious strategies businesses are adopting amid regulatory scrutiny. Dr. Scott Gottlieb, former FDA commissioner, discusses the resignation of the FDA's top vaccine official amid rising anti-vaccine sentiments and the U.S. measles outbreak. They highlight the urgent need to restore public trust in health systems and examine the complex interplay between politics and market dynamics.